Medium-Term Business Plan STS2030 Revision(FY2023 – FY2030)
This page introduces the medium-term management plan "STS2030 Revision" for 2023-2030.
In June 2020, we unveiled the SHIONOGI Group Vision (2030 Vision), setting out what we would like to accomplish by 2030, and formulated STS2030, a strategy to achieve this vision, which we have been implementing since the release of this plan.
SHIONOGI Group Vision
Building Innovation Platforms to Shape the Future of Healthcare
As Shionogi family we promise to:
- Imagine new ways to deliver innovation, and catalyze the formation of new healthcare platforms
- Create innovative products and deliver them worldwide compliantly with high quality at a fair price
- Embrace social responsibility and contribute to longer, healthier lives everywhere
Direction for the New Shionogi to Achieve 2030 Vision
Delivering value by providing healthcare as a service
(Healthcare as a Service:HaaS)
(Healthcare as a Service:HaaS)
- Generate new value and solve problems faced by patients and society through collaborative invention with a diverse range of partners
- Augment the strengths we have acquired through the discovery and development of “medicinal drugs,” and leverage those strengths
Continuously enhance our “strengths” as a drug-discovery-oriented pharma company, become the premier partner for other companies/industries for its unique strengths, build new platforms in the healthcare arena, and provide new value to society as a healthcare provider.
STS2030 Revision
Reflections on STS Phase 1
In STS Phase 1, we obtained domestic approval of ensitrelvir for COVID-19 treatment, launched products and services other than
prescription drugs, including a vaccine business, and strengthened governance.
Overall strategy and KPIs of STS 2030 Revision
STS2030 Revision KPI
<Shareholders return indicators>
(1) EPS (basic earnings per share)
(2) DOE (dividend on equity attributable to owners of the parent)
(3) ROE(return on equity attributable to owners of the parent)
Three pillars of the STS2030 Revision
(1) Continued growth of HIV franchise
(2) Continuous growth of COVID-19 treatments
(3) Expansion of new products and new businesses
Outline of STS Phase 2
Our basic policy of the STS Phase 2 is to achieve global top-line growth and establishment of growth drivers through aggressive investment, especially in the infectious disease area, and we will accelerate global expansion and growth investment based on the following six growth strategies.
Shionogi will work on the following social issues.
Creating value by solving healthcare social issues
1. Protect people from the threat of infectious diseases
2. Contribute to a healthy and prosperous life
3. Improve access to healthcare
Strengthen the management base and contribute to a sustainable society
4. Key Strategic Priorities (Global strategy, investment and financial strategies)
5. Transformation actions (Improving speed, globalizing corporate functions, and realizing DX platform)
6. Strengthen ESG management and contribute to a sustainable society (human capital management, sustainability)
Our view is that “people are the source of our competitiveness,” and to serve as a model that employees should aspire to emulate, we have established the Shionogi Way: Be the best that you can be to take on new challenges. To ensure that each and every employee grows into a person who embodies the Shionogi Way, we are propagating the SHIONOGI Group Values, which are values that are indispensable for realizing the 2030 Vision, and through, for example, the provision of training, we are helping our people to acquire abilities (capabilities and knowledge) that everyone should possess as well as abilities required for each individual role.
We recognize the importance of promoting initiatives to reduce negative impacts on customers and society in order to achieve both business growth and social sustainability. From the perspective of the importance of our company and the importance of society and the global environment, we recognize that "climate change" and "human rights" are issues that should be addressed in particular, and we are promoting initiatives.
Finance/investment strategy
Press Release
Presentation Materials
Past Medium-Term Business Plan
- Notice Regarding a New Medium-Term Business Plan (June 1, 2020)(Press Release)
- 2030 Vision and Medium-Term Business Plan (STS2030) (June 1, 2020)(Presentation Materials)
- Updates to Shionogi Growth Strategy (SGS2020) (October 31, 2016)
- Medium-Term Business Plan(SGS2020)(March 28, 2014)
- The 3rd Medium-Term Business Plan (March 16, 2010)
- The 2nd Medium-Term Business Plan (April 27, 2005)